WO2008085797A8 - miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - Google Patents

miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION Download PDF

Info

Publication number
WO2008085797A8
WO2008085797A8 PCT/US2007/089206 US2007089206W WO2008085797A8 WO 2008085797 A8 WO2008085797 A8 WO 2008085797A8 US 2007089206 W US2007089206 W US 2007089206W WO 2008085797 A8 WO2008085797 A8 WO 2008085797A8
Authority
WO
WIPO (PCT)
Prior art keywords
mir
pathways
targets
therapeutic intervention
regulated genes
Prior art date
Application number
PCT/US2007/089206
Other languages
French (fr)
Other versions
WO2008085797A3 (en
WO2008085797A2 (en
Inventor
Mike Byrom
Lubna Patrawala
Charles D Johnson
David Brown
Andreas G Bader
Original Assignee
Asuragen Inc
Mike Byrom
Lubna Patrawala
Charles D Johnson
David Brown
Andreas G Bader
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asuragen Inc, Mike Byrom, Lubna Patrawala, Charles D Johnson, David Brown, Andreas G Bader filed Critical Asuragen Inc
Priority to AU2007342068A priority Critical patent/AU2007342068A1/en
Priority to CA002671270A priority patent/CA2671270A1/en
Priority to EP07871756A priority patent/EP2102342A2/en
Publication of WO2008085797A2 publication Critical patent/WO2008085797A2/en
Publication of WO2008085797A3 publication Critical patent/WO2008085797A3/en
Priority to IL199161A priority patent/IL199161A0/en
Publication of WO2008085797A8 publication Critical patent/WO2008085797A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
PCT/US2007/089206 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION WO2008085797A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2007342068A AU2007342068A1 (en) 2006-12-08 2007-12-31 miR-16 regulated genes and pathways as targets for therapeutic intervention
CA002671270A CA2671270A1 (en) 2006-12-29 2007-12-31 Mir-16 regulated genes and pathways as targets for therapeutic intervention
EP07871756A EP2102342A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
IL199161A IL199161A0 (en) 2006-12-08 2009-06-04 mIR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86929506P 2006-12-08 2006-12-08
US60/869,295 2006-12-08
US88275806P 2006-12-29 2006-12-29
US60/882,758 2006-12-29
USPCT/US2007/087038 2007-12-10
PCT/US2007/087038 WO2008073923A2 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention

Publications (3)

Publication Number Publication Date
WO2008085797A2 WO2008085797A2 (en) 2008-07-17
WO2008085797A3 WO2008085797A3 (en) 2008-10-09
WO2008085797A8 true WO2008085797A8 (en) 2009-07-16

Family

ID=39512449

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/087038 WO2008073923A2 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention
PCT/US2007/089206 WO2008085797A2 (en) 2006-12-08 2007-12-31 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087038 WO2008073923A2 (en) 2006-12-08 2007-12-10 Mirna regulated genes and pathways as targets for therapeutic intervention

Country Status (5)

Country Link
EP (2) EP2102341A2 (en)
AU (2) AU2007333110A1 (en)
CA (1) CA2671302A1 (en)
IL (1) IL199161A0 (en)
WO (2) WO2008073923A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542501T3 (en) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use
US8513209B2 (en) 2007-11-09 2013-08-20 The Board Of Regents, The University Of Texas System Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
ES2397672T3 (en) 2007-12-05 2013-03-08 The Wistar Institute Of Anatomy And Biology Diagnostic method of lung cancers using genetic expression profiles in peripheral blood mononuclear cells
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2010094122A (en) * 2008-06-12 2010-04-30 Keio Gijuku Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
ES2562832T3 (en) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against the RGM protein for use in the treatment of degeneration of the retinal nerve fiber layer
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
LT2807192T (en) 2012-01-27 2018-07-25 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
WO2017005773A1 (en) * 2015-07-07 2017-01-12 Universite de Bordeaux Use of catenin- beta 1-targeting micrornas for treating liver cancer
US11692226B2 (en) 2017-07-31 2023-07-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Genotyping of SNPs to stratify cancer risk
EP3795585A4 (en) * 2018-05-16 2022-03-16 Genome and Company Pharmaceutical composition for preventing or treating cancer comprising lrit2 inhibitor as active ingredient
CN111972399B (en) * 2020-08-06 2021-11-30 温州医科大学 Preservation solution for maintaining activity of liver cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504605C (en) * 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
CN101296702B (en) * 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 Compositions and methods for the diagnosis and therapy of BCL2-associated cancers

Also Published As

Publication number Publication date
WO2008073923A2 (en) 2008-06-19
IL199161A0 (en) 2010-03-28
AU2007333110A1 (en) 2008-06-19
WO2008073923A3 (en) 2008-12-11
EP2102342A2 (en) 2009-09-23
EP2102341A2 (en) 2009-09-23
WO2008085797A3 (en) 2008-10-09
WO2008085797A2 (en) 2008-07-17
AU2007342068A1 (en) 2008-07-17
CA2671302A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2008085797A8 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008073921A3 (en) Mir-126 regulated genes and pathways as targets for therapeutic intervention
WO2008036776A3 (en) Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008073922A3 (en) Functions and targets of let-7 micro rnas
WO2009044899A1 (en) Nucleic acid capable of regulating the proliferation of cell
WO2009121152A8 (en) Gene signatures
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2010065787A3 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
EP3693464A3 (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2012058693A3 (en) Compositions and methods for inhibition of pcsk9 genes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780051044.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871756

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2671270

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007342068

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007871756

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007342068

Country of ref document: AU

Date of ref document: 20071231

Kind code of ref document: A